Isolagen Inc  (ILE) Trade Now »     Rate ILE  -  Discuss ILE  -  Add to Watch List        

Home

Analysis & Videos

Quotes

Bull or Bear

Discuss

ILE: Bull or Bear?

From:    SocialPicks  |  Blogsphere  |  All

SocialPicks Community

Updated Clinical Trial and FDA Decision Calendars ILE

73%

+0.00% in 239 days <> <> Below is a summary of updates to the www.BioMedReports.com database of 242 entries included in the FDA and Clinical Trial Calendars. The two web links below are for the FDA calendar home page and a recent article highlighting 14 extreme trades of companies with market caps below $200M with pending FDA decisions. http://biomedreports <wbr> </wbr> .com/fda-calendar.ht <wbr> </wbr> ml http://biomedreports <wbr> </wbr> .com/articles/most-p <wbr> </wbr> opular/627-trading-f <wbr> </wbr> da-decisions-14-extr <wbr> </wbr> eme-trades.html The FDA Calenda... Continue reading »

Stem Cell Index Down 7% in Past Week ILE

73%

-29.17% in 27 days (closed on 03/15/09) Stem Cell Index Down 7% in Past Week <> By Mike Havrilla on 2/15/09 The table at my website link below includes 26 companies in the ETF Innovators Emerging Stem Cell Index, which lost 7% of its market value in the past week (at 1,148 today) and posted a 15.2% loss over the past year on an equal-weight basis. http://www.etfinnovators.com/2009/02/stem-cell-index-down-7-i... Results for benchmark indexes and ETFs include gains of 1.5% for the Cosmetic and Restorative Medicine Index and losses of 1.2% for SPDR S&P Biotech (XBI), 18.7% for Healthcare Sector... Continue reading »

From the Blogosphere

Updated Clinical Trial and FDA Calendars

73%

Below is a summary of updates to the www.BioMedReports.com database of 242 entries included in the FDA and Clinical Trial Calendars. The two web links below are for the FDA calendar home page and a recent article highlighting 14 extreme trades of companies with market caps below $200M with pending FDA decisions. http://biomedreports.com/fda-calendar.html http://biomedreports.com/articles/most-popular/627-trading-fda-decisions-14-extreme-trades.html The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDU... Continue reading »

Trading FDA Decisions: 14 Extreme Trades

73%

Below is a summary of companies from the BioMedReports.com FDA Decision Date Calendar which have market caps below $200M, making them ideal candidates for extreme stock price volatility trades as their decision dates become imminent. Dyax Corp. (DYAX) secured a narrow approval from a FDA Advisory Panel in early February (with a 6-5-2 vote) for its Kalbitor (ecallantide or DX-88) BLA with a PDUFA date of 3/23/09, which is designated for priority review in the treatment of acute attacks of hereditary angioedema (HAE is a rare disorder marked by severe swelling which can be fatal if the throat ... Continue reading »

Stem Cell Index Soars on Lift of Funding Ban

73%

<>The accompanying table includes statistics for the 40 companies in the ETF Innovators Global Stem Cell and Regenerative Medicine Index, which is down 14.2% at a value of 3,387 from a 2/22/09 inception date value of 3,928. Most of the stocks got a major boost today from the widely anticipated executive order from President Obama to eliminate the restrictions on federal funding of stem cell research enacted in 2001 under President George W. Bush. The move allows federally funded researchers to use hundreds of new embryonic stem cell lines for what remains long-term but very promising research ... Continue reading »

Analysis of Stem Cell Index YTD

73%

The accompanying table includes statistics for the 40 companies in the ETF Innovators Global Stem Cell and Regenerative Medicine Index, which is down 13.8% at a value of 3,387 from a 2/22/09 inception date value of 3,928. The index is down 30.6% over the past year on an equal-weight basis, compared to losses of 31.2% for the Healthcare Sector SPDR (XLV), 19% for iShares Nasdaq Biotech (IBB), 14.7% for SPDR S&P Biotech (XBI), 29.7% for PowerShares Biotech & Genome (PBE), and 46.1% for the S&P 500 SPDR (SPY). Below is a profile for each company, including a summary of their business and researc... Continue reading »

Global Stem Cell and Regenerative Medicine Index

73%

The accompanying table (click to enlarge) includes 40 companies in the ETF Innovators Global Stem Cell and Regenerative Medicine Index, which represents an expansion of the Emerging Stem Cell Index I have written about previously. The expanded global index includes companies with market caps less than $1B at the index inception with a total market value of $3,814 as of the close today. As previously, I will track the total market value for a more comprehensive gauge of investor sentiment toward the space. The index is down 16.2% over the past year on an equal-weight basis, compared to losses... Continue reading »

... more »  

None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.